Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma

21Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The epidermal growth factor receptor (EGFR) signaling pathway is important in regulating biological behaviors in many malignancies. We explored whether expression and activation of EGFR and several components on its downstream pathways have prognostic significance in patients with esophageal squamous cell carcinoma (ESCC). Methods: Expression of EGFR, phosphorylated (p)-EGFR, AKT1, p-AKT1, AKT2, p-AKT2, ERK1, ERK2, p-ERK1/2, STAT3, and p-STAT3 was assessed by immunohistochemical analysis of tissue microarrays for 275 ESCC patients who had undergone complete three-field lymphadenectomy. Spearman rank correlation tests were used to determine the relationships among protein expression, and Cox regression analyses were performed to determine the prognostic factors on overall survival (OS). Results: p-EGFR expression was correlated statistically with all of the other phosphorylated markers. Gender, N stage, and p-AKT1 expression were found to be independent prognostic factors for OS. Increased expression of p-AKT1 was associated with decreased patient survival. EGFR and p-EGFR expression was not significantly associated with patient survival. Conclusion: Activation of AKT1 was associated with poor prognosis in ESCC.

Cite

CITATION STYLE

APA

Zhu, Z., Yu, W., Fu, X., Sun, M., Wei, Q., Li, D., … Zhao, K. (2015). Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma. Journal of Experimental and Clinical Cancer Research, 34(1). https://doi.org/10.1186/s13046-015-0212-z

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free